ESR1 and neoplasm: ER and/or Progesterone Receptor (PR)‐status are important biomarkers in breast cancers and, at present, defined clinically as the presence of at least 1% positive staining in tumor nuclei through Immuno‐Histo‐Chemistry (IHC) testing.